» BioMarin to purchase Prosensa and prioritise licensing for drisapersen Action Duchenne: "BioMarin Pharmaceutical have agreed to purchase Prosensa for $680 million , with two further payments of $80 million subject to drisapersen , Prosensa’s leading candidate for skipping exon 51 in Duchenne, being licensed in the USA by 15th May 2016 and Europe no later than 15th February 2017.
Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin said “BioMarin is dedicated to the rare disease community, and the acquisition of Prosensa fits strategically with our mission of delivering therapies that address serious unmet medical needs. We are committed to working closely with regulatory authorities worldwide in bringing a potentially breakthrough therapy to patients with this devastating condition.”"
'via Blog this'
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment